Senolytics May Reverse Age-Related Wound Healing Failure
Senescent cells disrupt skin repair with age — and emerging senotherapeutics may restore regenerative capacity in aged and diseased tissue.
Summary
As we age, wounds heal more slowly and chronic wounds become harder to treat. A key culprit appears to be senescent cells — damaged cells that stop dividing but refuse to die, instead releasing inflammatory signals that impair normal tissue repair. This review from the University of Minnesota examines how senescent cells accumulate in aging skin and disrupt the wound healing process, while also exploring a new class of drugs called senotherapeutics that target these cells. Multi-omic studies have revealed that senescent cells are not a single uniform population — different subsets play distinct roles in wound repair, some helpful in the short term and others persistently harmful. Preclinical evidence shows that clearing or suppressing these cells can restore tissue integrity and regenerative function, pointing toward a promising new therapeutic strategy for chronic wounds in older adults.
Detailed Summary
Wound healing becomes progressively impaired with aging, and chronic non-healing wounds represent a major clinical burden in older adults and those with conditions such as diabetes. Understanding why aged and diseased skin fails to repair itself is essential for developing better treatments. This review, published in Advances in Wound Care by researchers at the University of Minnesota's Masonic Institute on the Biology of Aging and Metabolism, synthesizes current knowledge on the relationship between cellular senescence and wound healing dysfunction.
Senescent cells (SnCs) are cells that have permanently exited the cell cycle in response to damage or stress. While transient senescence plays a beneficial role in normal wound repair — promoting inflammation clearance and tissue remodeling — persistent accumulation of SnCs in aged or chronically diseased skin becomes pathological. These cells secrete a pro-inflammatory cocktail known as the senescence-associated secretory phenotype (SASP), which disrupts the coordinated stages of healing and impairs regenerative signaling.
Recent advances in multi-omic analysis have illuminated the heterogeneity of SnC populations within the skin. Distinct subsets have been identified that differentially influence repair — a finding that has directly informed the development of more selective senotherapeutics. These include senolytics, which selectively eliminate SnCs, and senomorphics, which suppress the harmful SASP without killing the cells. Preclinical studies demonstrate meaningful improvements in tissue integrity and regenerative capacity following senotherapeutic treatment.
Despite this progress, significant gaps remain. The temporal dynamics of SnC populations across the wound healing timeline are poorly characterized, and distinguishing beneficial transient senescence from chronic pathogenic senescence remains technically challenging. Optimal therapeutic timing, delivery, and target specificity are unresolved.
Integrating multiomics approaches in both preclinical and clinical contexts will be necessary to refine senotherapeutic strategies. For aging individuals and those with chronic wounds, these therapies may eventually offer a targeted means to restore the skin's regenerative potential.
Key Findings
- Senescent cells accumulate in aged and damaged skin and impair the normal wound healing process via pro-inflammatory SASP signaling.
- Multi-omic profiling reveals distinct senescent cell subsets in skin with differing — sometimes opposing — effects on tissue repair.
- Senolytics and senomorphics show preclinical efficacy in restoring tissue integrity and regenerative capacity in aged skin.
- Transient senescence is beneficial during normal healing; persistent senescence is pathogenic and drives chronic wound failure.
- Optimal timing and delivery of senotherapeutics for wound healing remain unresolved and require further clinical investigation.
Methodology
This is a narrative review article synthesizing current preclinical and emerging clinical literature on cellular senescence and wound healing. The authors draw on multi-omic datasets and senotherapeutic intervention studies, primarily from animal models. No original experimental data are presented.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The review is narrative rather than systematic, limiting the ability to assess the strength of evidence quantitatively. Most supporting data come from preclinical models, and translation to human wound healing contexts remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: